AI-Discovered Lung Disease Drug Enters Phase III Trials in China
96Stats · x · 2026-07-14
A lung disease drug entirely discovered by AI has officially entered Phase III clinical trials in China.\n\nReports indicate that AI handled the entire R&D process for this drug, from identifying disease targets to designing the drug molecules. Currently, 320 名患者 are participating in the trial to verify its actual efficacy, which has shown positive therapeutic potential in earlier stages.
Related event: AI-Discovered Drug Enters Phase III Trials in China(2 posts)→
More from Research
- SUFLECA shows NOC-based correspondence can improve CAD-to-image alignment — ducha_aiki · 2026-07-21
- OpenAI-style autonomous researchers could become real scientific collaborators — Promptmethus · 2026-07-21
- Soft Clamp cuts tool-call overuse in multi-teacher distillation, from 13.7% to 9.0% — antgroup · 2026-07-21
- ShotPlan adds learnable planning tokens for cinematic multi-shot video generation — Tele-AI · 2026-07-21
- A silicon photonic reservoir chip compensates fiber distortion in real time at 28 Gbps — bravo_abad · 2026-07-21
- A developer maps out six design rules for CLIs that humans and AI agents can both use — yujiezha · 2026-07-21